Loading...
•
Mar 31, 2025
Pacira Q1 2025 Earnings Report
Reported financial results for the first quarter of 2025
Key Takeaways
Pacira BioSciences reported total revenues of $168.9 million for the first quarter of 2025, a slight increase from the prior year. Net income was $4.8 million, or $0.10 per share, compared to $9.0 million, or $0.19 per share, in the first quarter of 2024. Adjusted EBITDA was $44.1 million.
Total revenues increased slightly to $168.9 million in Q1 2025 from $167.1 million in Q1 2024.
GAAP net income decreased to $4.8 million ($0.10 per share) in Q1 2025 from $9.0 million ($0.19 per share) in Q1 2024.
Non-GAAP net income was $30.0 million ($0.62 per diluted share) in Q1 2025 compared to $31.1 million ($0.62 per diluted share) in Q1 2024.
Cash, cash equivalents and available-for-sale investments totaled $493.6 million at the end of Q1 2025.
Revenue by Segment
Forward Guidance
Pacira is reiterating its full-year 2025 financial guidance.
Positive Outlook
- Total revenue is expected to be between $725 million and $765 million.
- Non-GAAP gross margin is anticipated to be between 76% and 78%.
- Non-GAAP R&D expense is projected to be between $90 million and $105 million.
- Non-GAAP SG&A expense is expected to be between $290 million and $320 million.
- Stock-based compensation is estimated to be between $56 million and $61 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...